This study investigates advanced pancreatic ductal adenocarcinoma. It looks at the effects of combining an investigational medication with a standard chemotherapy regimen called AG.
The purpose of this study is to evaluate the safety and effectiveness of the investigational medication when used with AG. The study seeks to understand how the combination affects the immune system and its potential benefits for patients.
- Who can participate: Adults aged 18 to 80 with confirmed advanced pancreatic ductal adenocarcinoma who have not received prior systemic therapy may participate. Key eligibility includes having measurable disease and adequate organ function.
- Study details: Participants will receive either the investigational medication with AG or AG alone.
How understandable was the trial content above?
Hard to understand
Easy to understand